欧美特黄aaaaa,欧洲成人在线,狠狠综合久久久久综合,亚洲视频一区网站

服務(wù)熱線

15021010459
技術(shù)文章
當(dāng)前位置:主頁 > 技術(shù)文章 > Ariad抗癌藥Iclusig重返市場

Ariad抗癌藥Iclusig重返市場

更新時(shí)間:2014-01-20 點(diǎn)擊次數(shù):1631

    去年Ariad Pharmaceuticals公司業(yè)績由于主打抗癌藥物Iclusig被緊急下架而遭受重創(chuàng)。公司一度陷入困境并將其在美國的員工裁員160人,約占美 國分部總員工數(shù)的40%,以節(jié)省開支。不過現(xiàn)在Ariad Pharmaceuticals公司迎來一絲曙光。公司已經(jīng)著手將Iclusig重新推向市場。此次Ariad將把Iclusig的適用癥范圍縮小,并在 藥物包裝上標(biāo)明可能出現(xiàn)的副作用如心臟病、血液凝塊等。不過由于Iclusig適用范圍變小,公司的收入可能也會大受影響。為解決這一問題公司計(jì)劃申請重 啟此前被FDA下令暫停的關(guān)于Iclusig治療慢性白血病的研究計(jì)劃以達(dá)到亡羊補(bǔ)牢的作用。

    不過Ariad Pharmaceuticals公司的這一系列舉措能否獲得預(yù)期效果還需要等待公司2014年*季度財(cái)報(bào)公布后才能知曉。

詳細(xì)英文報(bào)道:

    Last year, Ariad Pharmaceuticals ($ARIA) watched more than $2.5 billion melt off its market cap when the cancer-fighting Iclusig began a downward spiral that would eventually remove it from the market. But now begins the rebuilding project, as the Cambridge, MA, drugmaker has relaunched its sole product with a lot of ground to make up.

    The drug is now indicated for a smaller group of leukemia patients than before, and it carries a serious boxed warning about the risk of clotting and heart failure that got it pulled from shelves in the fall. But it is for sale, and that puts Ariad in a better place than many predicted at its nadir.

    "We are back on track," CEO Harvey Berger told Bloomberg last month. "We'll enter 2014 largely where we were as we started off the fall in September."

    Of course, that's not entirely the case. Losing more than half of its value forced Ariad to considerably thin its ranks, laying off 40% of its U.S. workforce--or 160 employees--in an effort to save $26 million. Now the company plans to gradually ramp up stateside sales with the help of specialty pharmacy Biologics, Inc., first looking to transition the case-by-case patients who were still using the drug during its marketing hiatus.

    And the company has a long way to go on the R&D side. When the storm over Iclusig began, Ariad was in the process of testing the drug in a broader population, but an FDA-imposed clinical hold led the company to discontinue a Phase III study on patients with newly diagnosed chronic myeloid leukemia and put the brakes on a fleet of Phase II studies designed to expand the drug's market. Berger has said that Ariad is yet to decide just how to move forward with its paused programs.

    Still, the biotech is undeniably sitting prettier than it was just two months ago, and its next big test will come when Q1 sales figures roll in.——(華雅干細(xì)胞整理報(bào)道)

2025 版權(quán)所有 © 重慶市華雅干細(xì)胞技術(shù)有限公司  備案號:渝ICP備14000349號-4 sitemap.xml 管理登陸 技術(shù)支持:化工儀器網(wǎng)

地址:重慶市江北區(qū)金渝大道153號8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

重慶市華雅干細(xì)胞技術(shù)有限公司主要經(jīng)營干細(xì)胞研究 干細(xì)胞治療產(chǎn)品 生物試劑 實(shí)驗(yàn)耗材 藥物研發(fā)等產(chǎn)品。

關(guān)注我們

服務(wù)熱線

400-021-2200

掃一掃,關(guān)注我們

成人黄色免费看| 国产精品美女久久福利网站| 成人免费无遮挡无码黄漫视频| А中文在线天堂| 亚洲香蕉影视在线播放| 亚洲天堂2017无码| 男人扒开添女人下部有好处吗| 亚洲va欧美va| 无码人妻久久一区二区三区免费丨| 99久久综合九九亚洲| 亚洲AV片在线观看| 亚洲理论精品午夜电影| 亚洲国产日韩欧美综合久久| 成人国产欧美精品一区二区| 污的网站在线观看| 亚洲AV天堂一区二区香蕉| 五月槐花香电视剧全集免费| 久久国产免费观看精品| 大量国产激情视频在线观看| 乌克兰极品少妇XXXX做受| 久久精品AⅤ无码中文字字幕重口| 污视频在线观看| 中字幕视频在线永久在线观看免费| 日本视频中文字幕| 人人射人人爽| 试看20分钟做受| 精品久久久久久亚洲偷窥一区| 亚洲欧美另类一区| 日韩精品一区二区三区在线观看| 国产乱人伦偷精品视频免下载| 欧美日韩一区二区三区在线播放| 国模极品一区二区三区| 夜夜躁狠狠躁日日躁| 国产人与ZOXXXX另类| 无码人妻丰满熟妇区五十路百度| 亚洲日本图色| 国产视频日韩| 金梅瓶肉交白话文| 麻豆专区免费一区二区| 国内精品久久久久久影院老狼| 一晚上被男人做了好几次|